Impel Neuropharma

Impel Pharmaceuticals, Inc. operates as a clinical stage biotechnology firm that develops medical devices. It offers intranasal drug treatments for central nervous system (CNS) disorders. The firm’s product candidates include TRUDHESA, INP105, and INP107. The company was founded by Rodney J. Y. Ho, John D. Hoekman, and Michael P. Hite in 2008 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Impel Pharmaceuticals is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

The FDA approval celebration is over, and the real work of selling is about to begin.

Why Impel NeuroPharma Gained 17% Today Then Faded

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares of common stock are being offered by Impel. In addition, Impel intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the offering price, less underwriting discounts and commissions.

Impel NeuroPharma Announces Launch of Proposed Public Offering

The FDA approves Impel's (IMPL) Trudhesa nasal spray for the acute treatment of migraine with or without aura in adults.

Impel (IMPL) Gets FDA Nod for Trudhesa in Migraine Treatment

Impel NeuroPharma Inc. (NASDAQ: IMPL) secured U.S. FDA approval for its Trudhesa nasal spray as an acute treatment of migraine in adults (with or without aura). Shares of the company opened more than 40% up on Friday but lost the entire gain later on.

This analyst raised his price target on Impel NeuroPharma by more than 50%

The U.S. Food and Drug Administration has approved Impel NeuroPharma's Trudhesa to treat migraine headaches, the Seattle company announced Friday.

Impel NeuroPharma, fresh off IPO, gets FDA approval for nasal spray that treats migraines

Cowen has raised Impel NeuroPharma Inc's (NASDAQ:IMPL) price target to $55 from $35, with an Outperform rating, after the FDA approved Trudhesa for the acute treatment of migraine. The analyst sees more than 100% upside for the stock.

Cowen Beefs Up Target Price For This Medical Device Firm

The stock price of Impel NeuroPharma, Inc. (NASDAQ: IMPL) increased by over 10% during intraday trading. This is why it happened.

IMPL Stock: Over 10% Increase Explanation

The company's nasal spray got a green light from the FDA to treat migraine headaches.

Why Impel NeuroPharma Stock Is Soaring Today

The FDA has approved Impel NeuroPharma Inc's (NASDAQ: IMPL) Trudhesa (dihydroergotamine mesylate) nasal spray for the acute treatment of migraine with or without aura in adults.  Using Impel's Precision Olfactory Delivery technology, Trudhesa gently delivers dihydroergotamine mesylate to the bloodstream through the vascular-rich upper nasal space.

FDA Gives Nod To Nasal Spray Migraine Treatment From Impel NeuroPharma; Stock Jumps

TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich Upper Nasal Space

Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine

Impel NeuroPharma, Inc. (IMPL) CEO Adrian Adams on Q2 2021 Results - Earnings Call Transcript

TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021

Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced it will host a live webcast on Monday, August 16, 2021 at 8:30 a.m. ET to report its second quarter 2021 financial results and provide a business update.

Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

Study Shows TRUDHESA™ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief

Impel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal Headache

SEATTLE, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that Adrian Adams, chief executive officer, will present on a panel titled “For Headaches THIS Big – The Evolution of Migraine Therapeutic Landscape” at the 2021 Wedbush Pacgrow Virtual Healthcare Conference on Tuesday, August 10, 2021 at 8:00-8:30 a.m. ET.

Impel NeuroPharma to Present at the 2021 Wedbush Pacgrow Virtual Healthcare Conference

SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced the closing of a $50 million debt facility with Oxford Finance LLC and Silicon Valley Bank, of which the first $20 million was funded at closing.

Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley Bank

– Completed successful IPO raising approximately $80.0 million in gross proceeds – – NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 – – Strengthened commercial capabilities with expanded management team and strategic collaboration with Veeva Systems –

Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business Update

Initiative Features Artwork from Internationally Renowned Artist Ed Fairburn, Specially Developed to Illustrate the Complexities of Migraine Initiative Features Artwork from Internationally Renowned Artist Ed Fairburn, Specially Developed to Illustrate the Complexities of Migraine

Impel NeuroPharma Launches Reroute Migraine Relief, Educational Initiative That Brings to Life the Underrecognized Connection Between Migraine, the Brain and Gut

Agiliti Inc

Rain Therapeutics

Latham Group

Treace Medical Concepts

Latham Group, Treace Medical Concepts, Impel NeuroPharma, and Rain Therapeutic are on the Nasdaq. Agiliti is on the New York Stock Exchange.

Five companies Begin Trading Friday

The news: Seattle-based biotech company Impel NeuroPharma raised $80 million in its initial public offering and will begin trading on the NASDAQ Friday.

Impel Neuropharma raises $80M in Washington state's first IPO of 2021

SEATTLE, April 22, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today announced the pricing of its initial public offering of 5,333,334 shares of its common stock at a price to the public of $15.00 per share. All of the shares are being offered by Impel. The shares are expected to begin trading on The Nasdaq Global Market on April 23, 2021 under the symbol “IMPL.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Impel, are expected to be $80.0 million. In addition, Impel has granted the underwriters a 30-day option to purchase up to an additional 800,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on April 27, 2021, subject to the satisfaction of customary closing conditions.

News for Impel Neuropharma Stock (IMPL)